Drug General Information |
Drug ID |
D0C6KI
|
Former ID |
DNC006010
|
Drug Name |
CB-676475
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H13ClFN3O2
|
InChI |
InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)
|
InChIKey |
YHUIUSRCUKUUQA-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
8034284, 11061242, 15646968, 39301631, 47646534, 50112883, 51371558, 85787121, 103396736, 113911350, 129797746, 134343215, 141722357, 162009830, 163123735, 163620773, 163686099, 179236116, 185989929, 196400770, 204356589, 223400489, 226087984, 229067699, 249565925, 252451475, 252473974
|
Target and Pathway |
Target(s) |
mRNA of VEGFR1 |
Target Info |
Inhibitor |
[2]
|
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[3]
|
Vascular endothelial growth factor receptor 3 |
Target Info |
Inhibitor |
[3]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
HIF-1 signaling pathway
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Focal adhesion
|
Transcriptional misregulation in cancer
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
VEGF signaling pathway
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_9:TNFalpha Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
Glypican 1 network
|
HIF-2-alpha transcription factor network
|
S1P3 pathway
|
VEGF and VEGFR signaling network
|
VEGFR1 specific signals
|
Signaling events mediated by VEGFR1 and VEGFR2hif2pathway:HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY networkvegf_vegfr_pathway:VEGF and VEGFR signaling network
|
VEGFR3 signaling in lymphatic endothelium
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerization
|
WikiPathways
|
Focal Adhesion
|
Signaling by VEGF
|
AngiogenesisWP306:Focal Adhesion
|
Nifedipine Activity
|
Cardiac Progenitor Differentiation
|
AngiogenesisWP1919:Signaling by VEGF
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8245). |
---|
REF 2 | Bioorg Med Chem. 2010 May 15;18(10):3575-87. Epub 2010 Mar 27.Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. |
---|
REF 3 | Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33. Epub 2005 Oct 10.Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. |